Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 13 of 13

List	Outcome	Time frame
Primary	Progression free survival at 12 months	12 months
Secondary	The proportion of Complete haematological remission	5 years
Secondary	The proportion of Major molecular response defined by a BCR-ABL/ABL ≤ 0.1% in bone marrow	5 years
Secondary	The proportion of Complete molecular response	5 years
Secondary	Event free survival	5 years
Secondary	Relapse free survival	5 years
Secondary	Progression free survival	5 years
Secondary	The proportion of Detection of a T315I or F317 BCR-ABL TK mutation	5 years
Secondary	The proportion of Molecular progression	5 years
Secondary	Overall survival	5 years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	5 years
Secondary	Death during induction	2 months
Secondary	Death in complete remission	5 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02888990/registered